在癌症中,XPO1 R749Q突变与POLE突变同时发生,可以向克服化学抵抗
Tulasigeri M Totiger1, Wannasiri Chiraphapphaiboon2, Yasmine Baca3
1Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, Florida.
癌症中的EXPORTIN-1 (XPO1) R749Q突变与POLE突变和化学抵抗有关. 结合XPO1抑制剂和拓酶I抑制剂显示出协同作用的抗瘤效应,并在临床前模型中克服了耐药性.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 输出蛋白-1 (XPO1) 对细胞存活至关重要,其突变在癌症中被发现.
- 基因组分析显示,在各种癌症中,XPO1热点突变经常发生.
研究的目的:
- 在大量癌症患者中识别和描述XPO1变异.
- 研究XPO1 R749Q突变的功能和临床影响.
主要方法:
- 对217,570名癌症患者的大规模基因组分析.
- 对XPO1.1的同位素细胞系分析和结构建模.
- 复合图书馆查和药物组合研究.
- 在异种移植小鼠模型中的评估.
主要成果:
- 在固体瘤中确定了XPO1 R749Q突变,在子宫内膜和结直肠癌中丰富,并与POLE突变同时发生.
- XPO1 R749Q增强了蛋白质的输出,并赋予了对拓酶I抑制剂的耐药性.
- 与XPO1和拓酶I抑制剂的联合治疗显示出协同作用的抗瘤作用,并在临床前模型中克服了耐药性.
结论:
- 在POLE突变瘤中选择了XPO1变异,特别是R749Q,并与化学抵抗相关.
- 针对XPO1与I型拓酶抑制剂结合,为XPO1R749Q突变癌症患者提供了一个有前途的治疗策略.
更多相关视频
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancers Originate from Somatic Mutations in a Single Cell
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Abnormal Proliferation
